Yes I too doubt that CSL would be interested although some diversification that has some marketing synergy may be prudent for them.
Ironic is it not that when QFT was handed over to Cellestis, CSL was the Australian supplier for the Tuburculin Skin Test.
My original post really was thrown into the mix just to remind us or the origins of this Australian developed and commercialised product.
As a former employee of F H Faulding, I remember in the 1980's (at a time when they were successfully penetrating international markets) the company was subject to foreign takeover attempts by first Nicholas Kiwi and then Glaxo. The second of the takeover attempts was fostered and supported by the Board but strongly resisted by its own employees and through strong lobying of the SA State and Federal governments thwarted the Glaxo attempt. Faulding survived for another twenty years but eventually the Company under the late Ed Tweddel sold out to Mayne who then promptly sold off most of what they could to foreign owners.
Sad isn't it all!
CST Price at posting:
$3.43 Sentiment: Hold Disclosure: Held
